Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Table 2 Rates of overall survival at 6 months and 1 year according to the RTOG RPA class, the HER-2 status and the delivery of trastuzumab

	n	Median Survival (months)	6 months [CI95%]	1 year [CI95%]	P value
Whole population	130	7.43 (5.52 -9.73)	54.9 [46.8; 64.3]	35.8 [28; 45.7]
RTOG RPA				44.6 [34.3; 58.1]	0.001
Class I-II	78	9.63 (7.69-15.72)	65.9 [56; 77.5]	23.9 [14.2; 40.4]
Class III	48	3.52 (2.86-7.36)	37.7 [26; 54.7]
					0.004
HER-2 negative patients	78	5.88 [3.75; 9.63]	48.7 [37.7; 63]	26.1 [16.8; 40.7]
HER-2 positive patients not treated with trastuzumab	20	5.65 [2.60; 12.49]	45.5 [31.3; 66.1]	29.2 [17-50.2]
HER-2 positive patients treated with trastuzumab	32	19.53 [9.27; NA]	77.1 [63.5; 93.6]	62.6 [47.2; 83]
Trastuzumab	10	9.17 (5.52-NA)	63.6 [40.7; 99.5]	43.6 [21.8; 87.4]	0.113
Stopped	22	20.91 (19.53-NA)	94.4 [84.4; 100]	88.5 [74.8; 100]
Continued

ISSN: 1471-2407